Model projections on the required coverage of syringe distribution to prevent HIV epidemics among injecting drug users

Journal of Acquired Immune Deficiency Syndromes

Volumn 42, Issue 3, 2006, Pages 355-361

  Vickerman, Peter ^a   Hickman, Matthew ^b   Rhodes, Tim ^a   Watts, Charlotte ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Coverage; HIV; Injecting drug use; Modeling; Syringe distribution

Indexed keywords

ARTICLE; DRUG USE; EPIDEMIC; HEALTH BEHAVIOR; HEALTH CARE POLICY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MATHEMATICAL MODEL; NEEDLE; PRIORITY JOURNAL; SAFETY; SYRINGE; VIRUS TRANSMISSION;

HIV INFECTIONS; HUMANS; MODELS, THEORETICAL; NEEDLE SHARING; PREVALENCE; SENSITIVITY AND SPECIFICITY; SUBSTANCE ABUSE, INTRAVENOUS; SYRINGES;

EID: 33745877267     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000219788.73539.47     Document Type: Article

References (61)

1. Preventing HIV transmission - the role of sterile needles and bleach. In: Norman J, Vlahov D, Moses LE eds. Institute of Medicine. Washington, DC: National Academy Press; 1995.
2. Gibson DR, Flynn N, Perales D. Effectiveness of syringe exchange programs in reducing HIV risk behavior and HIV seroconversion among injecting drug users. AIDS. 2001;15:1329-1341.
3. Des Jarlais DC. Structural interventions to reduce HIV transmission among injecting drug users. AIDS. 2000;14(suppl 1):S41-S46.
4. Hurley SF, Jolley DJ, Kaldor JM. Effectiveness of needle-exchange programmes for prevention of HIV infection. Lancet. 1997;349(9068): 1797-1800.
5. Lurie P, Drucker E. An opportunity lost: HIV infections associated with lack of a national needle-exchange programme in the USA. Lancet. 1997;349(9052):604-608.
6. MacDonald M, Law MG, Kaldor JM, et al. Effectiveness of needle and syringe programmes for preventing HIV transmission. Int J Drug Policy. 2003;14:353-357.
7. Taussig JA, Weinstein B, Burris S, et al. Syringe laws and pharmacy regulations are structural constraints on HIV prevention in the US. AIDS. 2000;14(suppl 1):S47-S51.
8. Strathdee SA, van Ameijden EJ, Mesquita F, et al. Can HIV epidemics among injection drug users be prevented? AIDS. 1998;12(suppl A): S71-S79.
9. United Nations. General assembly declaration of commitment on HIV/AIDS. 2001. Available at: http://www.un.org/ga/aids/docs/aress262.pdf. Accessed June 2005.
10. Jones TS, Vlahov D. Use of sterile syringes and aseptic drug preparation are important components of HIV prevention among injection drug users. J Acquir Immune Defic Syndr. 1998;18(suppl 1):S1-S5.
11. Strathdee S, Vlahov D. The effectiveness of needle exchange programs: a review of the science and policy. AID Science. 2001;1(16):1-31.
12. WHO. Task force for the urgent response to the epidemics of sexually transmitted infections in eastern Europe and central Asia. 2000. WHO regional office for Europe.
13. Monterroso ER, Hamburger ME, Vlahov D, et al. Prevention of HIV infection in street-recruited injection drug users. The Collaborative Injection Drug User Study (CIDUS). J Acquir Immune Defic Syndr. 2000;25(1):63-70.
14. Parsons J, Hickman M, Turnbull PJ, et al. Over a decade of syringe exchange: results from 1997 UK survey. Addiction. 2002;97(7):845-850.
15. Anonymous. Update: syringe exchange programs - United States, 1998. MMWR Morb Mortal Wkly Rep. 2001;50(19):384-387.
16. Des Jarlais DC, Marmor M, Friedmann P, et al. HIV incidence among injection drug users in New York City, 1992-1997: evidence for a declining epidemic. Am J Public Health. 2000;90(3):352-359.
17. Kaplan EH, Heimer R. A circulation theory of needle exchange. AIDS. 1994;8(5):567-574. [editorial].
18. Murray JM, Law MG, Gao Z, et al. The impact of behavioural changes on the prevalence of HIV and hepatitis C among injecting drug users. Int J Epidemiol. 2003;32:708-714.
19. Kaplan E, O'Keefe E. Let the needles do the talking! Evaluating the New Haven needle exchange. Interfaces. 1993;23(1):7-26.
20. Donoghoe MC, Stimson GV, Dolan K, et al. Changes in HIV risk behaviour in clients of syringe-exchange schemes in England and Scotland. AIDS. 1989;3(5):267-272.
21. Des Jarlais C, Perlis T, Friedman SR, et al. Behavioral risk reduction in a declining HIV epidemic: injection drug users in New York City, 1990-1997. Am J Public Health. 2000;90(7):1112-1116.
22. Hartgers C, Buning EC, van Santen GW, et al. The impact of the needle and syringe-exchange programme in Amsterdam on injecting risk behaviour. AIDS. 1989;3(9):571-576.
23. Bluthenthal RN, Kral AH, Gee L, et al. The effect of syringe exchange use on high-risk injection drug users: a cohort study. AIDS. 2000; 14(5):605-611.
24. Rhodes T, Davis M, Judd A. Hepatitis C and its risk management among drug injectors in London: renewing harm reduction in the context of uncertainty. Addiction. 2004;99(5):621-633.
25. McKeganey N, Abel M, Taylor A, et al. The preparedness to share injecting equipment: an analysis using vignettes. Addiction. 1995;90(9):1253-1260.
26. Donoghoe M, Dolan K, Stimson G. Life-style factors and social circumstances of syringe sharing in injecting drug users. Br J Addict. 1992;87:993-1003.
27. Wood E, Tyndall MW, Spittal PM, et al. Factors associated with persistent high-risk syringe sharing in the presence of an established needle exchange programme. AIDS. 2002;16(6):941-943.
28. Anderson R, May RM. The basic model: dynamics. In: Infectious Diseases of Humans: Dynamics and Control. Oxford, UK: Oxford University Press; 1992:122-143.
29. Friedman SR, Kottiri BJ, Neaigus A, et al. Network-related mechanisms may help explain long-term HIV-1 seroprevalence levels that remain high but do not approach population-group saturation. Am J Epidemiol. 2000;152(10):913-922.
30. Des Jarlais C, Friedman S, Sotheran JL, et al. Continuity and change with an HIV epidemic. JAMA. 1994;271:121-127.
31. Schoenbaum EE, Hartel DM, Gourevitch MN. Needle exchange use among a cohort of injecting drug users. AIDS. 1996;10(14):1729-1734.
32. Hope VD, Judd A, Hickman M, et al. HIV prevalence among injecting drug users in England and Wales 1990 to 2003: evidence for increased transmission in recent years. AIDS. 2005;19(11): 1207-1214.
33. Judd A, Hickman M, Jones S, et al. Incidence of hepatitis C virus among new injecting drug users in London - prospective cohort study. Br Med J. 2005;330(7481):24-25.
34. Judd A, Hutchinson S, Wadd S, et al. Prevalence of, and risk factors for, hepatitis C virus infection among recent initiates to injecting in London and Glasgow - cross sectional analysis. J Viral Hepat. 2005;12(6):655-662.
35. Vickerman P, Watts CH. The impact of an HIV prevention intervention for injecting drug users in Svetlogorsk, Belarus: model predictions. Int J Drug Policy. 2002;13:149-164.
36. Hickman M, Higgins V, Hope VD, et al. Injecting drug use in Brighton, Liverpool, and London: best estimates of prevalence and coverage of public health indicators. J Epidemiol Community Health. 2004;58:766-771.
37. Hickman M, Higgins V, Hope V, et al. Injecting drug use in Brighton, Liverpool, and London: best estimates of prevalence and coverage of public health indicators. J Epidemiol Community Health. 2004;58(9):766-771.
38. Prins M, Hernandez Aguado IH, Brettle RP, et al. Pre-AIDS mortality from natural causes associated with HIV disease progression: evidence from the European Seroconverter Study among injecting drug users. AIDS. 1997;11(14):1747-1756.
39. Pezzotti P, Galai N, Vlahov D, et al. Direct comparison of time to AIDS and infectious disease death between HIV seroconverter injection drug users in Italy and the United States: results from the ALIVE and ISS studies. AIDS link to intravenous experiences. Italian Seroconversion Study. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20(3):275-282.
40. Hunter GM, Donoghoe MC, Stimson GV, et al. Changes in the injecting risk behaviour of injecting drug users in London, 1990-1993. AIDS. 1995;9(5):493-501.
41. Frischer M, Bloor M, Green S, et al. Reduction in needle sharing among community wide samples of injecting drug users. Int J STD AIDS. 1992;3:288-290.
42. Bluthenthal RN, Malik MR, Grau LE, et al. Sterile syringe access conditions and variations in HIV risk among drug injectors in three cities. Addiction. 2004;99(9):1136-1146.
43. Abdala N, Crowe M, Tolstov Y, et al. Survival of human immunodeficiency virus type 1 after rinsing injection syringes with different cleaning solutions. Subst Use Misuse. 2004; 39(4):581-600.
44. Abdala N, Gleghorn A, Carney JM, et al. Can HIV-1-contaminated syringes be disinfected? Implications for transmission among injection drug users. J Acquir Immune Defic Syndr. 2001;28:487-494.
45. Blumenthal RN, Kral A, Lorvick J, et al. Impact of law enforcement on syringe exchange programs. Med Anthropol. 1997;18:61-83.
46. Burris S. Law as a structural factor in the spread of communicable disease. Houston Law Review. 1999;36(5):1755-1786.
47. Rhodes T, Mikhailova L, Sarang A, et al. Situational factors influencing drug injecting, risk reduction and syringe exchange in Togliatti City, Russian Federation: a qualitative study of micro risk environment. Soc Sci Med. 2003;57(1):39-54.
48. Hope VD, Goldberg D, de Souza L, et al. Shooting up infections among injecting drug users in the United Kingdom, 2002. An update: December 2003. Health Protection Agency, SCIEH, NPHSW, CDSCNI, CRDHB, UASSG 2003.
49. Heimer R, Khoshnood K, Bigg D, et al. Syringe use and reuse: effects of syringe exchange programs in four cities. J Acquir Immune Defic Syndr. 1998;18(suppl 1):S37-S44.
50. Des Jarlais DC, Perlis T, Arasteh K, et al. "Informed altruism" and "partner restriction" in the reduction of HIV infection in injecting drug users entering detoxification treatment in New York City, 1990-2001. J Acquir Immune Defic Syndr. 2004;35(2):158-166.
51. Judd A, Hickman M, Jones S, et al. Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study. BMJ. 2005;330(7481):24-25.
52. Hope VD, Hickman M, Tilling K. Capturing crack-cocaine use: estimating the prevalence of crack-cocaine use in London using capture-recapture with covariates. Addiction. 2005;100(11): 1701-1708.
53. Des Jarlais DC, Perils T, Arasteh K, et al. HIV incidence among injection drug users in New York City, 1990 to 2002: use of serologic test algorithm to assess expansion of HIV prevention services. Am J Public Health. 2005;95(8):1439-1444.
54. Kumaranayake L, Vickerman P, Walker D, et al. The cost-effectiveness of HIV preventive measures among injecting drug users in Svetlogorsk, Belarus. Addiction. 2004;99:1565-1576.
55. Vickerman P, Kumaranayake L, Balakireva O, Guinness L, et al. The cost-effectiveness of expanding harm reduction activities for injecting drug users in Odessa, Ukraine. Sex Transm Dis. 2006. In press.
56. Des Jarlais DC, Perlis T, Friedman SR, et al. Declining seroprevalence in a very large HIV epidemic: injecting drug users in New York City, 1991 to 1996. Am J Public Health. 1998;88(12):1801-1806.
57. Stimson GV, Hunter GM, Donoghoe MC, et al. HIV-1 prevalence in community-wide samples of injecting drug users in London, 1990-1993. AIDS. 1996;10(6):657-666.
58. Zule WA. Risk and reciprocity: HIV and the injection drug user. J Psychoactive Drugs. 1992;24(3):243-249.
59. Strathdee S. Sexual HIV transmission in the context of injection drug use: implications for interventions. Int J Drug Policy. 2003;14:79-81.
60. Kaplan EH, Heimer R. A model-based estimate of HIV infectivity via needle sharing. J Acquir Immune Defic Syndr. 1992; 5(11):1116-1118.
61. Hudgens MG, Longini IM Jr, Vanichseni S, et al. Subtype-specific transmission probabilities for human immunodeficiency virus among injecting drug users in Bangkok, Thailand. Am J Epidemiol. 2002;155:159-168.